Best Practices in Hematologic Malignancies – December 2017 Vol 8

← Back to Issue


Leukemia and Lymphoma

Besponsa a New Treatment Option for Patients with Relapsed/Refractory B-Cell ALL

On August 17, 2017, the FDA approved inotuzumab ozogamicin (Besponsa), a targeted therapy, for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The drug blocks cancer growth by binding to B-cell ALL cells that express CD22. The FDA designated inotuzu­mab ozogamicin as an orphan drug and applied its priority review for this approval.

“For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low. These patients have few treatments available, and today’s approval provides a new, targeted treatment option,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The FDA approval of inotuzumab ozogamicin was based on a randomized clinical trial of 326 patients with relapsed or refractory B-cell ALL who had received 1 or 2 previous treatments. Among the 218 evaluable patients, 35.8% of those receiving inotuzumab ozogamicin achieved complete remission that lasted a median of 8 months. Of the patients who received an alternative chemotherapy regimen, 17.4% achieved complete remission lasting a median of 4.9 months.

The common side effects reported with inotuzumab ozogamicin include thrombocytopenia, neutropenia, leukopenia, infection, anemia, fatigue, hemorrhage, pyrexia, nausea, headache, febrile neutropenia, liver damage, abdominal pain, and hyper­bilirubinemia. Serious side effects attributed to the use of inotuzumab ozogamicin include myelosuppression, infusion-related reactions, and QT interval prolongation.

Inotuzumab ozogamicin was approved with a boxed warning about the risk for hepatotoxicity, including veno-occlusive disease or sinusoidal obstruction syndrome, as well as the increased mortality risk in patients who use the drug after certain stem cell transplants.

Related Articles
Multiple Myeloma - January 2, 2018

Darzalex Combined with Pomalidomide and Dexamethasone Approved for Relapsed/Refractory Multiple Myeloma

Daratumumab (Darzalex), in combination with pomalidomide (Pomalyst) and dexamethasone, for the treatment of patients with multiple myeloma who have received at least 2 previous therapies, including lenalidomide (Revlimid) and a [ Read More ]

Leukemia and Lymphoma - January 2, 2018

Mylotarg Now Approved for the Treatment of Patients with CD33-Positive AML

On September 1, 2017, the FDA approved gemtuzumab ozogamicin (Mylotarg) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), as well as patients aged ≥2 years [ Read More ]